Abstract B049: Phase II study of NUC-3373, leucovorin, irinotecan (NUFIRI) + bevacizumab vs FOLFIRI + bevacizumab for the second-line treatment of patients with advanced/metastatic colorectal cancer (NuTide:323)
Year: 2023
Type: conference-abstract
Source: Molecular Cancer Therapeutics
Authors: Richard H Wilson, Kristen K Ciombor, Andrew L Coveler, Janet S Graham, Benjamin L Schlechter, Thomas J George, Elena Élez, TR Jeffry Evans, Jordan Berlin, Aimery de Gramont, Fiona G McKissock, Elisabeth Oelmann, Jeffrey D Bloss, Giulia Martini, Jaafar Bennouna, Dominik P Modest, Julien Taieb, Josep Tabernero
Institutions: Beatson West of Scotland Cancer Centre, University of Glasgow, Vanderbilt University Medical Center, University of Washington, Fred Hutch Cancer Center, Dana-Farber Cancer Institute, UF Health Cancer Center, Vall d'Hebron Institute of Oncology, Institut Hospitalier Franco Britannique, Nucana (United Kingdom), University of Campania "Luigi Vanvitelli", Centre Hospitalier Universitaire de Nantes, Charité - Universitätsmedizin Berlin, Université Paris Cité, Hôpital Européen Georges-Pompidou
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4389239792